Acceleron Pharma (XLRN) Stock News
NASDAQ:XLRN - Nasdaq -
XLRN Latest News, Press Relases and Analysis
3 Dow Stocks to Take Seriously in 2023
The top Dow stocks for 2023 are all big free cash flow generators that ought to be able to cope with whatever next year brings.
Avoro Capital Urges Acceleron Shareholders Not to Tender Into Merck’s Inadequate Offer
Merck Is a Dividend Play Ready to Get Back in Gear
Pfizer has been beating MRK stock in 2021, but that relative performance may reverse next year, with new drugs and acquisitions ahead.
Is Merck's Planned Acquisition of Acceleron in Trouble?
There's nothing to worry about with a recent delay.
Mentions: MRK
Avoro Capital Releases Presentation Detailing Why Acceleron Shareholders Should Not Tender Into Merck’s Inadequate Offer
The Daily Biotech Pulse: Double Dose Of Positive Tidings For Merck, Alkermes Slips On Partial Termination Of J&J Licensing Deal, Amgen Migraine Drug Data
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Merck Gets Antitrust Nod For Acceleron Deal In Germany, Austria, Announces...
Acceleron Pharma (XLRN) Reports Q3 Loss, Lags Revenue Estimates
Acceleron (XLRN) delivered earnings and revenue surprises of 1.04% and -6.62%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Acceleron Reports Third Quarter 2021 Financial Results
Farallon Capital Opposes Terms of Merck’s Acceleron Takeover
Another top-10 holder in Acceleron Pharma Inc. has come out against its proposed $11.5 billion takeover by Merck & Co. Inc., arguing the sale price undervalues the company.
Mentions: MRK
Merck Pushes Acceleron Buyout By Refiling For Antitrust Review
Merck & Co Inc (NYSE: MRK) revealed that it had temporarily withdrawn its premerger notification and report form. The company said it plans to refile today....
Mentions: MRK
Earnings Preview: Acceleron Pharma (XLRN) Q3 Earnings Expected to Decline
Acceleron (XLRN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates CXP, XLRN, HRC, DSPG; Shareholders are Encouraged to Contact the Firm
NEW YORK, NY / ACCESSWIRE / October 28, 2021 / Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: Columbia Property Trust, Inc. (NYSE:CXP) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to funds managed by Pacific Investment Management Company LLC for $19.30 per share in cash. If you are a Columbia Property
Merck (MRK) Beats on Q3 Earnings & Sales, Ups 2021 View
Merck (MRK) beats Q3 estimates for earnings and sales. It raises financial guidance for 2021. The stock moves up in the pre-market trading session.
Avoro Capital Issues Open Letter to Fellow Acceleron Pharma Shareholders
Acceleron Announces Third Quarter 2021 REBLOZYL® Net Sales
Merck (MRK) to Report Q3 Earnings: What's in the Cards?
Investor focus is likely to be on the sales of Merck's (MRK) blockbuster oncology medicine, Keytruda, when the company reports Q3 earnings.
SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates AZPN, HRC, KOR, XLRN; Shareholders are Encouraged to Contact the Firm
NEW YORK, NY / ACCESSWIRE / October 23, 2021 / Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: Aspen Technology, Inc. (NASDAQ:AZPN) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its merger with certain of Emerson Electric Co.'s industrial software businesses. Under the terms of the agreement, Aspen shareholders will
SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates UMPQ, XLRN, ADMS, AZPN; Shareholders are Encouraged to Contact the Firm
NEW YORK, NY / ACCESSWIRE / October 21, 2021 / Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: Umpqua Holdings Corporation (NASDAQ:UMPQ) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to Columbia Banking System, Inc. Under the terms of the agreement, Umpqua shareholders will receive 0.5958 of a share of Columbia
Bristol-Myers Plans to Exit Acceleron Stake With Merck Deal
Bristol-Myers Squibb Co. is planning to tender its shares in Acceleron Pharma Inc. after Merck & Co. agreed to buy the biotechnology company for $11.5 billion, according to people with knowledge of the matter.
ACCELERON PHARMA ALERT: Investors Should Contact Bragar Eagel & Squire, P.C. Over Tender Offer for XLRN Shares
SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates COLB, AZPN, XLRN; Shareholders are Encouraged to Contact the Firm
NEW YORK, NY / ACCESSWIRE / October 15, 2021 / Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: Columbia Banking System, Inc. (NASDAQ:COLB) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its merger with Umpqua Holdings Corporation. Under the terms of the agreement, Umpqua shareholders will receive 0.5958 of a share of
Bristol-Myers Is Said to Have Weighed Offer for Acceleron
Acceleron Pharma Inc. engaged with several companies including Bristol-Myers Squibb Co. to gauge their interest in a potential acquisition before Merck & Co. agreed to buy the company for $11.5 billion in the biggest biotechnology deal of 2021, according to a person familiar with the matter.
SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates XLRN, ECHO, KRA, EBMT; Shareholders are Encouraged to Contact the Firm
NEW YORK, NY / ACCESSWIRE / October 8, 2021 / Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: Acceleron Pharma Inc. (NASDAQ:XLRN) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to Merck & Co., Inc. for $180.00 per share in cash. If you are an Acceleron shareholder, click here to learn more about your rights and
Is an Acquisition of Acceleron a Smart Move for Merck?
Merck will pick up a promising pipeline candidate with the deal.
Mentions: MRK